Alembic Pharmaceuticals Ltd. - Research Center
533573 APLLTD Group (A) BSE data
Add to watchlist
| Results |
Annual
|
| Statement | |
| More |
Annual results in brief
(Rs crore)
| Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | |
|---|---|---|---|---|---|
| Sales | 5,051.44 | 4,132.55 | 3,660.27 | 2,945.26 | 2,956.45 |
| Operating profit | 1,572.23 | 1,202.90 | 878.67 | 632.53 | 633.28 |
| Interest | 12.77 | 25.19 | 14.87 | 2.22 | 3.09 |
| Gross profit | 1,569.19 | 1,312.46 | 870.22 | 636.98 | 632.61 |
| EPS (Rs) | 59.80 | 51.43 | 32.42 | 22.39 | 22.85 |
Annual
results in details
| Mar ' 21 | Mar ' 20 | Mar ' 19 | Mar ' 18 | Mar ' 17 | |
|---|---|---|---|---|---|
| Other income | 9.73 | 134.75 | 6.42 | 6.67 | 2.42 |
| Stock adjustment | -157.13 | -176.50 | -80.41 | -36.18 | -47.90 |
| Raw material | 1,175.71 | 978.13 | 850.05 | 725.75 | 703.87 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 948.27 | 806.37 | 684.45 | 582.72 | 527.46 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 1,512.36 | 1,321.65 | 1,327.51 | 1,040.44 | 1,139.74 |
| Provisions made | - | - | - | - | - |
| Depreciation | 152.60 | 135.67 | 105.59 | 101.76 | 82.90 |
| Taxation | 241.20 | 197.39 | 153.42 | 113.23 | 119.08 |
| Net profit / loss | 1,175.39 | 969.40 | 611.21 | 421.99 | 430.63 |
| Extra ordinary item | - | -10.00 | - | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 39.31 | 37.70 | 37.70 | 37.70 | 37.70 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 31.12 | 29.11 | 24.01 | 21.48 | 21.42 |
| GPM (%) | 31.00 | 30.76 | 23.73 | 21.58 | 21.38 |
| NPM (%) | 23.22 | 22.72 | 16.67 | 14.30 | 14.55 |
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis